Entropy Technologies LP Has $796,000 Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Entropy Technologies LP reduced its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 15.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,310 shares of the medical research company’s stock after selling 815 shares during the period. Entropy Technologies LP’s holdings in Charles River Laboratories International were worth $796,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in CRL. Empirical Finance LLC increased its position in Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after purchasing an additional 53 shares in the last quarter. OLD National Bancorp IN grew its stake in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after buying an additional 59 shares during the last quarter. Fiduciary Financial Group LLC increased its holdings in shares of Charles River Laboratories International by 3.9% during the fourth quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after buying an additional 63 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the last quarter. Finally, M&T Bank Corp boosted its holdings in shares of Charles River Laboratories International by 3.4% during the 3rd quarter. M&T Bank Corp now owns 2,001 shares of the medical research company’s stock valued at $394,000 after acquiring an additional 66 shares in the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Trading Down 3.1 %

NYSE CRL opened at $154.93 on Wednesday. Charles River Laboratories International, Inc. has a one year low of $154.01 and a one year high of $275.00. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14. The business has a 50 day simple moving average of $178.90 and a 200 day simple moving average of $192.24. The stock has a market capitalization of $7.92 billion, a P/E ratio of 19.39, a P/E/G ratio of 6.47 and a beta of 1.37.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on CRL. Evercore ISI upped their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. TD Cowen upped their price objective on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. CLSA downgraded shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price on the stock. in a research report on Monday, November 18th. JPMorgan Chase & Co. decreased their price target on shares of Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday, February 3rd. Finally, Morgan Stanley cut their price target on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 5th. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).